UroGen Pharma Ltd. (URGN)
10.09
-0.11 (-1.08%)
At close: Apr 24, 2025, 3:59 PM
10.11
0.20%
After-hours: Apr 24, 2025, 04:05 PM EDT
-1.08% (1D)
| Bid | 9.91 |
| Market Cap | 465.09M |
| Revenue (ttm) | 90.4M |
| Net Income (ttm) | -126.87M |
| EPS (ttm) | -2.96 |
| PE Ratio (ttm) | -3.41 |
| Forward PE | -16.47 |
| Analyst | Buy |
| Ask | 10.7 |
| Volume | 519,715 |
| Avg. Volume (20D) | 423,247 |
| Open | 10.11 |
| Previous Close | 10.20 |
| Day's Range | 9.96 - 10.16 |
| 52-Week Range | 8.94 - 20.70 |
| Beta | 0.81 |
About URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms...
Industry Biotechnology
Sector Healthcare
IPO Date May 4, 2017
Employees 235
Stock Exchange NASDAQ
Ticker Symbol URGN
Website https://www.urogen.com
Analyst Forecast
According to 7 analyst ratings, the average rating for URGN stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 207.23% from the latest price.
Stock ForecastsNext Earnings Release
UroGen Pharma Ltd. is scheduled to release its earnings on May 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+4.63%
UroGen Pharma shares are trading higher after the ...
Unlock content with
Pro Subscription
6 months ago
+0%
UroGen Pharma shares are trading higher after the company announced FDA acceptance of its new drug application for UGN-102.
